Personalized Medicine Isn’t Paying The Bills Yet; More Science Needed
This article was originally published in The Gray Sheet
Executive Summary
Though the promise of personalized medicine has been widely touted, firms focusing on targeted therapies and companion diagnostics are not getting much bang for their buck - yet
You may also be interested in...
Personalized Partnering: Drug, Dx Firms Should Team, Not Necessarily Merge
Industry leaders disagree on whether collaborations or mergers are the best structure for effective drug/diagnostic collaborations
Personalized Partnering: Drug, Dx Firms Should Team, Not Necessarily Merge
Industry leaders disagree on whether collaborations or mergers are the best structure for effective drug/diagnostic collaborations
Novartis Pharma To Add Diagnostics Unit In 2009
Novartis' Pharma division will establish a molecular diagnostics unit in 2009, Pharma CEO Joseph Jimenez said during the firm's Nov. 19 R&D day